|
|
||||||||||
|
J Am Coll Cardiol, 1991; 18:1804-1810 © 1991 by the American College of Cardiology Foundation |
Cardiovascular Division, Washington University School of Medicine, St. Louis, Missouri 63110.
To determine whether platelet-activating factor is a specific mediator of cyclic flow variations in damaged stenotic arteries and whether it contributes to reocclusion after thrombolysis, femoral arteries in anesthetized dogs were subjected to mural injury and high grade stenosis to induce cyclic flow variations (28 +/- 4/h) or methods selected to elicit platelet-rich and fibrin-rich thrombosis. Oral administration of a novel triazolobenzodiazepine (U46,195 [10 mg/kg]) that selectively inhibits platelet-activating factor abolished cyclic flow variations within 120 min and for greater than or equal to 2 h thereafter compared with persistent flow variations in dogs given saline solution. Platelet aggregation induced ex vivo with platelet-activating factor was inhibited in parallel with in vivo inhibition of cyclic flow variations after administration of U46,195. However, buccal mucosa bleeding time was not affected. After thrombosis, administration of U46,195 before thrombolysis was induced with human recombinant tissue-type plasminogen activator (1.7 mg/kg intravenously over 60 min) prevented reocclusion within 120 min in six of eight and six of seven arteries by platelet-rich and fibrin-rich thrombosis, respectively. In contrast, in dogs given saline solution, reocclusion occurred in eight of eight (p = 0.007 compared with U46,195) and five of eight arteries by platelet-rich and fibrin-rich thrombosis, respectively. Thus, both cyclic flow variations and reocclusion after thrombolysis appear to be mediated in part by platelet-activating factor. The results suggest that inhibition of platelet-activating factor with specific antagonists may be useful in reducing platelet-mediated occlusion of coronary arteries without eliciting bleeding.
This article has been cited by other articles:
![]() |
H. Arakawa, J.-Y. Qian, D. Baatar, K. Karasawa, Y. Asada, Y. Sasaguri, E. R. Miller, J. L. Witztum, and H. Ueno Local Expression of Platelet-Activating Factor-Acetylhydrolase Reduces Accumulation of Oxidized Lipoproteins and Inhibits Inflammation, Shear Stress-Induced Thrombosis, and Neointima Formation in Balloon-Injured Carotid Arteries in Nonhyperlipidemic Rabbits Circulation, June 21, 2005; 111(24): 3302 - 3309. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Montrucchio, G. Alloatti, and G. Camussi Role of Platelet-Activating Factor in Cardiovascular Pathophysiology Physiol Rev, October 1, 2000; 80(4): 1669 - 1699. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Fujise, L. Stacy, P. Beck, E. T.H. Yeh, A. Chuang, T. A. Brock, and J. T. Willerson Differential Effects of Endothelin Receptor Activation on Cyclic Flow Variations in Rat Mesenteric Arteries Circulation, November 18, 1997; 96(10): 3641 - 3646. [Abstract] [Full Text] |
||||
![]() |
G. Montrucchio, E. Lupia, A. De Martino, L. Silvestro, S. R. Savu, G. Cacace, P.G. De Filippi, G. Emanuelli, and G. Camussi Plasmin Promotes an Endothelium-Dependent Adhesion of Neutrophils : Involvement of Platelet Activating Factor and P-Selectin Circulation, June 15, 1996; 93(12): 2152 - 2160. [Abstract] [Full Text] |
||||
![]() |
H. W. Mueller, C. A. Haught, J. M. McNatt, K. Cui, S. J. Gaskell, D. A. Johnston, and J. T. Willerson Measurement of Platelet-Activating Factor in a Canine Model of Coronary Thrombosis and in Endarterectomy Samples From Patients With Advanced Coronary Artery Disease Circ. Res., July 1, 1995; 77(1): 54 - 63. [Abstract] [Full Text] |
||||
![]() |
H. S. Demrow, P. R. Slane, and J. D. Folts Administration of Wine and Grape Juice Inhibits In Vivo Platelet Activity and Thrombosis in Stenosed Canine Coronary Arteries Circulation, February 15, 1995; 91(4): 1182 - 1188. [Abstract] [Full Text] |
||||
![]() |
W. H. Beierwaltes, D'A. L. Potter, O. A. Carretero, and D. H. Sigmon Nitric Oxide Synthesis Inhibition Blocks Reversal of Two-Kidney, One Clip Renovascular Hypertension After Unclipping Hypertension, February 1, 1995; 25(2): 174 - 179. [Abstract] [Full Text] |
||||
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |